The purpose of the Connect® MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they relate to clinical outcomes of patients with newly diagnosed Myelodysplastic Syndrome (MDS), Idiopathic Cytopenia of Undetermined Significance (ICUS) or Acute Myeloid Leukemia (AML) in routine clinical practice and evaluate molecular and cellular markers that may provide further prognostic classification and/or might be predictive of therapy outcomes.
Principal Investigator
Aaron H. Chevinsky, MD
Contact
Riverside Cancer Clinical Team
757-534-6890
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd. Suite 201
Newport News, VA 23601
Peninsula Cancer Institute
120 King’s Way, Suite 3100
Williamsburg, VA 23185
Peninsula Cancer Institute
7544B Medical Drive
Gloucester, VA 23061
Cancer Specialists of Tidewater
1200 First Colonial Road, #204
Virginia Beach, VA 23454
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Cancer Specialists of Tidewater
5839 Harbour View Blvd., #100
Suffolk, VA 23435
Status
Recruiting
Category
Oncology
Study #